Besremi
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Ropeginterferon alfa-2b
- Made by
- AOP Orphan Pharmaceuticals GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (BESREMi). It describes the substance, not this exact product.
Interferon alfa belongs to the class of type I interferons, which exhibit their cellular effects in polycythemia vera and essential thrombocythemia in the bone marrow by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR).
Binding to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) and activator of transcription (STAT) proteins.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-25
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | AOP Orphan Pharmaceuticals GmbH |
|---|---|
| Active substance | Ropeginterferon alfa-2b |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L03AB15 · Cancer treatments and immune-system medicines |
| Authorised on | 2019-02-15 |
| Last updated by the regulator | 2026-04-24 |
| EMA product number | EMEA/H/C/004128 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).